NEUBASE THERAPEUTICS INC (NBSE) Stock Price & Overview
NASDAQ:NBSE • US64132K2015
The current stock price of NBSE is 0.378 USD. Today NBSE is down by -3.2%. In the past month the price decreased by -13.84%. In the past year, price decreased by -90.27%.
NBSE Key Statistics
- Market Cap
- 1.418M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.30
- Dividend Yield
- N/A
NBSE Stock Performance
NBSE Stock Chart
NBSE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NBSE. When comparing the yearly performance of all stocks, NBSE is a bad performer in the overall market: 98.24% of all stocks are doing better.
NBSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBSE. While NBSE seems to be doing ok healthwise, there are quite some concerns on its profitability.
NBSE Earnings
NBSE Forecast & Estimates
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.
NBSE Groups
Sector & Classification
NBSE Financial Highlights
Over the last trailing twelve months NBSE reported a non-GAAP Earnings per Share(EPS) of -7.3. The EPS increased by 55.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.74% | ||
| ROE | -150.22% | ||
| Debt/Equity | 0 |
NBSE Ownership
NBSE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBSE
Company Profile
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania. The company went IPO on 2014-05-28. The company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. The company uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. The company also focused on identifying and evaluating multiple indications for potential development.
Company Info
NEUBASE THERAPEUTICS INC
350 Technology Drive
Pittsburgh PENNSYLVANIA 15219 US
CEO: Dietrich Stephan
Employees: 37
Phone: 14127633350
NEUBASE THERAPEUTICS INC / NBSE FAQ
What does NEUBASE THERAPEUTICS INC do?
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania. The company went IPO on 2014-05-28. The company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. The company uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. The company also focused on identifying and evaluating multiple indications for potential development.
Can you provide the latest stock price for NEUBASE THERAPEUTICS INC?
The current stock price of NBSE is 0.378 USD. The price decreased by -3.2% in the last trading session.
What is the dividend status of NEUBASE THERAPEUTICS INC?
NBSE does not pay a dividend.
How is the ChartMill rating for NEUBASE THERAPEUTICS INC?
NBSE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for NEUBASE THERAPEUTICS INC?
NEUBASE THERAPEUTICS INC (NBSE) has a market capitalization of 1.42M USD. This makes NBSE a Nano Cap stock.